Time- and Sex-Dependent Effects of Fingolimod Treatment in a Mouse Model of Alzheimer’s Disease
Biomolecules · 2023
DOI: 10.3390/biom13020331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Pablo Bascuñana und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Section of Neuropathology, Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo and Oslo Univ…. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Southern and Eastern Norway Regional Health Authority, Barnekreftforeningen.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is the most common cause of dementia. Fingolimod has previously shown beneficial effects in different animal models of AD. However, it has shown contradictory effects when it has been applied at early disease stages. Our objective was to evaluate fingolimod in two different treatment paradigms. To address this aim, we treated male and female APP-transgenic mice for 50 days, starting either before plaque deposition at 50 days of age (early) or at 125 days of age (late). To evaluate the effects, we investigated the neuroinflammatory and glial markers, the Aβ load, and the concentration of the brain-derived neurotrophic factor (BDNF). We found a reduced Aβ load only in male animals in the late treatment paradigm. These animals also showed reduced microglia activation and reduced IL-1β. No other treatment group showed any difference in comparison to the controls. On the other hand, we detected a linear correlation between BDNF and the brain Aβ concentrations. The fingolimod treatment has shown beneficial effects in AD models, but the outcome depends on the neuroinflammatory state at the start of the treatment. Thus, according to our data, a fingolimod treatment would be effective after the onset of the first AD symptoms, mainly affecting the neuroinflammatory reaction to the ongoing Aβ deposition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Section of Neuropathology, Translational Neurodegeneration Research and Neuropathology Lab, University of Oslo and Oslo University Hospital, Sognsvannsveien 20, 0372 Oslo, Norway.
- Pahnke Laboratory (Drug Development and Chemical Biology), Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck and University Medical Center Schleswig-Holstein, Ratzeburger Allee 160, 23538 Lübeck,…
- Department of Pharmacology, Faculty of Medicine, University of Latvia, Jelgavas iela 3, 1004 Rīga, Latvia.
- Department of Neurobiology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
ORCID-Profile: Pablo Bascuñana, Mirjam Brackhan, Thomas Brüning, Jens Pahnke
Förderung
- Deutsche Forschungsgemeinschaft
- Southern and Eastern Norway Regional Health Authority
- Barnekreftforeningen
- Technology Agency of the Czech Republic
- The Research Council of Norway
- Latvian Council of Science
- Federal Ministry of Education and Research
- Austrian Research Promotion Agency
Zitieren
APA
Bascuñana, P., Brackhan, M., Möhle, L., Wu, J., Brüning, T., Eiriz, I., Jansone, B., & Pahnke, J. (2023). Time- and Sex-Dependent Effects of Fingolimod Treatment in a Mouse Model of Alzheimer’s Disease. Biomolecules. https://doi.org/10.3390/biom13020331
Vancouver
Bascuñana P, Brackhan M, Möhle L, Wu J, Brüning T, Eiriz I, et al. Time- and Sex-Dependent Effects of Fingolimod Treatment in a Mouse Model of Alzheimer’s Disease. Biomolecules. 2023. doi:10.3390/biom13020331
BibTeX
@article{Bascuana2023,
author = {Bascuñana, Pablo and Brackhan, Mirjam and Möhle, Luisa and Wu, Jingyun and Brüning, Thomas and Eiriz, Ivan and Jansone, Baiba and Pahnke, Jens},
title = {Time- and Sex-Dependent Effects of Fingolimod Treatment in a Mouse Model of Alzheimer’s Disease},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13020331}
}
EUVIMED